Russian pharmaceutical company PSK Pharma has obtained a registration certificate for its drug Ranibizumab PSK for treating severe retinal diseases, specifically the neovascular form of age-related macular degeneration and proliferative diabetic retinopathy, a serious complication of diabetes.
“The active substance, ranibizumab, is a monoclonal antibody fragment that treats eye conditions by blocking vascular endothelial growth factor A. This prevents the growth of abnormal blood vessels and reduces edema, allowing patients to preserve and improve their eyesight,” the company said.
The drug is a solution for intraocular injection, which allows the active ingredient to be delivered directly to the foci, ensuring high efficacy and minimal side effects.
The demand for ranibizumab medications in Russia is high, due to the prevalence of the diseases listed above, according to PSK Pharma. Since the start of the year, over 30,000 packages of such medicines have been purchased through government procurement. Ranibizumab is included in the list of vital and essential drugs (VED).
The new product will be manufactured at PSK Pharma’s own plant in the Dubna special economic zone near Moscow.